Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) EPS (Basic): 2021-2024

Historic EPS (Basic) for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to -$4.43.

  • Amylyx Pharmaceuticals' EPS (Basic) rose 65.42% to -$0.37 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.79, marking a year-over-year increase of 53.14%. This contributed to the annual value of -$4.43 for FY2024, which is 706.85% down from last year.
  • Amylyx Pharmaceuticals' EPS (Basic) amounted to -$4.43 in FY2024, which was down 706.85% from $0.73 recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' EPS (Basic) ranged from a high of $0.73 in FY2023 and a low of -$13.35 during FY2021.
  • In the last 3 years, Amylyx Pharmaceuticals' EPS (Basic) had a median value of -$3.39 in 2022 and averaged -$2.36.
  • In the last 5 years, Amylyx Pharmaceuticals' EPS (Basic) surged by 121.53% in 2023 and then plummeted by 706.85% in 2024.
  • Amylyx Pharmaceuticals' EPS (Basic) (Yearly) stood at -$13.35 in 2021, then soared by 74.61% to -$3.39 in 2022, then soared by 121.53% to $0.73 in 2023, then crashed by 706.85% to -$4.43 in 2024.